ULBI vs. GMAB
ULBI (Ultralife Corporation) and GMAB (Genmab A/S) are both stocks. ULBI operates in Electrical Equipment & Parts (Industrials), while GMAB operates in Biotechnology (Healthcare). Over the past 10 years, ULBI returned 3.10%/yr vs 4.28%/yr for GMAB. At a 0.09 correlation, their price movements are largely independent.
Performance
ULBI vs. GMAB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ULBI achieves a 15.03% return, which is significantly higher than GMAB's -18.57% return. Over the past 10 years, ULBI has underperformed GMAB with an annualized return of 3.10%, while GMAB has yielded a comparatively higher 4.28% annualized return.
ULBI
- 1D
- 1.23%
- 1M
- 8.40%
- YTD
- 15.03%
- 6M
- 14.43%
- 1Y
- -14.99%
- 3Y*
- 10.86%
- 5Y*
- -5.76%
- 10Y*
- 3.10%
GMAB
- 1D
- -0.63%
- 1M
- -5.50%
- YTD
- -18.57%
- 6M
- -19.90%
- 1Y
- 9.90%
- 3Y*
- -13.28%
- 5Y*
- -10.53%
- 10Y*
- 4.28%
ULBI vs. GMAB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ULBI Ultralife Corporation | 15.03% | -23.22% | 9.24% | 76.68% | -36.09% | -6.65% | -12.45% | 9.48% | 3.05% | 32.32% |
GMAB Genmab A/S | -18.57% | 47.58% | -34.45% | -24.87% | 7.13% | -2.71% | 82.09% | 35.54% | -0.61% | -0.04% |
Correlation
The correlation between ULBI and GMAB is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2009 | 0.09 |
Fundamentals
ULBI:
$109.60M
GMAB:
$16.01B
ULBI:
-$0.49
GMAB:
$4.10
ULBI:
0.58
GMAB:
1.81
ULBI:
0.85
GMAB:
2.82
ULBI:
$187.86M
GMAB:
$8.84B
ULBI:
$43.39M
GMAB:
$8.27B
ULBI:
$6.73M
GMAB:
$3.81B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ULBI vs. GMAB — Risk / Return Rank
ULBI
GMAB
ULBI vs. GMAB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ultralife Corporation (ULBI) and Genmab A/S (GMAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ULBI | GMAB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.53 | ||
| Sortino ratioReturn per unit of downside risk | -0.61 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.07 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | -0.36 | 0.27 | -0.62 |
| Martin ratioReturn relative to average drawdown | -0.58 | 0.58 | -1.16 |
Loading charts...
Drawdowns
ULBI vs. GMAB - Drawdown Comparison
The maximum ULBI drawdown since its inception was -92.90%, which is greater than GMAB's maximum drawdown of -84.20%. Use the drawdown chart below to compare losses from any high point for ULBI and GMAB.
Loading charts...
Drawdown Indicators
| ULBI | GMAB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.90% | -84.20% | -8.70% |
Max Drawdown (1Y)Largest decline over 1 year | -44.69% | -32.51% | -12.18% |
Max Drawdown (3Y)Largest decline over 3 years | -68.83% | -57.44% | -11.39% |
Max Drawdown (5Y)Largest decline over 5 years | -68.83% | -63.10% | -5.73% |
Max Drawdown (10Y)Largest decline over 10 years | -68.83% | -63.10% | -5.73% |
Current DrawdownCurrent decline from peak | -73.14% | -48.52% | -24.62% |
Average DrawdownAverage peak-to-trough decline | -63.48% | -31.09% | -32.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.64% | 14.86% | +12.78% |
Volatility
ULBI vs. GMAB - Volatility Comparison
Ultralife Corporation (ULBI) has a higher volatility of 18.04% compared to Genmab A/S (GMAB) at 12.15%. This indicates that ULBI's price experiences larger fluctuations and is considered to be riskier than GMAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ULBI | GMAB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.04% | 12.15% | +5.89% |
Volatility (6M)Calculated over the trailing 6-month period | 41.57% | 25.57% | +16.00% |
Volatility (1Y)Calculated over the trailing 1-year period | 57.63% | 34.45% | +23.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 58.99% | 33.47% | +25.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 54.53% | 35.19% | +19.34% |
Dividends
ULBI vs. GMAB - Dividend Comparison
Neither ULBI nor GMAB has paid dividends to shareholders.
Financials
ULBI vs. GMAB - Financials Comparison
This section allows you to compare key financial metrics between Ultralife Corporation and Genmab A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ULBI vs. GMAB - Profitability Comparison
ULBI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ultralife Corporation reported a gross profit of 10.11M and revenue of 47.45M. Therefore, the gross margin over that period was 21.3%.
GMAB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Genmab A/S reported a gross profit of 834.08M and revenue of 899.32M. Therefore, the gross margin over that period was 92.8%.
ULBI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ultralife Corporation reported an operating income of -215.00K and revenue of 47.45M, resulting in an operating margin of -0.5%.
GMAB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Genmab A/S reported an operating income of 225.83M and revenue of 899.32M, resulting in an operating margin of 25.1%.
ULBI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ultralife Corporation reported a net income of -451.00K and revenue of 47.45M, resulting in a net margin of -1.0%.
GMAB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Genmab A/S reported a net income of 53.20M and revenue of 899.32M, resulting in a net margin of 5.9%.
Frequently Asked Questions
ULBI and GMAB have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ULBI has higher volatility (18.04%) compared to GMAB (12.15%). In terms of maximum drawdown, ULBI dropped -92.90% vs GMAB's -84.20%.
GMAB currently has the higher Sharpe Ratio (0.25 vs -0.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ULBI and GMAB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer